Interview 6 Sep 2017 The CAR-T Race is Far from Over: This CEO is Exploring a New Avenue Gilead has just splashed out $12 billion for Kite Pharma, and the FDA is currently reviewing Novartis’ Marketing Approval Application for the first-ever CAR-T therapy. I sat down with Gregg Sando of Cell Medica to hear the perspective of a biotech vying for a piece of the pie. Though he spent 20 years in investment […] September 6, 2017 - 6 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
Interview 4 Sep 2017 Meet this Blockbuster Developer turned Partner at a Headlining VC Kevin Johnson told me the story and lessons of his career, from CTO of Cambridge Antibody Technology to General Partner at Medicxi. Since starting his biotech career as the lead developer of one of biotech’s biggest success stories, Humira, Kevin Johnson has continued in biotech as a force to be reckoned with. He joined the […] September 4, 2017 - 7 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
Interview 24 Jul 2017 Discussing Open Science with the Head of Translation at The Francis Crick Institute Officially opened less than a year ago, The Francis Crick Institute is already conducting top-level biomedical research, has launched two spin-outs and struck research partnerships with both AstraZeneca and GlaxoSmithKline. I spoke to the Head of Translation, Dr. Véronique Birault, to learn more about the Crick’s unique model of translation and the key for its […] July 24, 2017 - 5 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Interview 20 Jul 2017 Video – DNA Molecular Combing for the Early Detection of Genetic Diseases It’s been more than a month since Refresh, but the topic of our last expert track is as current as ever: DNA analysis for the early detection of genetic diseases. Charles Caulliez, Director of Corporate Business Development at Genomic Vision, started his talk by introducing the company: In 2004, Aaron Bensimon (CEO) founded Genomic Vision as […] July 20, 2017 - 3 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
Interview 17 Jul 2017 Pinning Down Elusive Targets: Interviewing the Co-Founder & CSO of Heptares Heptares is expanding into a range of indications with its GPCR platform. I caught up with CSO & co-founder Fiona Marshall to hear more about the strategy. Fiona Marshall has always worked on G-protein coupled receptors, or GPCRs for short. These entities are key to many eukaryotic signaling pathways, and because of their prevalence, they’re […] July 17, 2017 - 6 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
Interview 13 Jul 2017 Video: How to Access EU Funding as an Innovative Biotech Two experts, one success story. From the European Commission to the European Investment Bank, our experts told us what to do to access EU funding as an innovative and young Biotech company! This Refresh Expert Track kicked off with the Head of Unit at the European Commission, Cornelius Schmaltz, who introduced the focus for health research […] July 13, 2017 - 2 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
Interview 13 Jul 2017 Meet Denmark’s Youngest Professor and Serial Synbio Entrepreneur Philip sat down to chat with Professor and serial entrepreneur Morten Sommer about his career in the second Labiotech Hangout. At 35, Morten Sommer is not only the youngest full professor ever in Denmark but also the entrepreneur behind a number of synbio-based companies. For Labiotech’s second Hangout on June 29th, Philip probed his thoughts […] July 13, 2017 - 4 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
Interview 11 Jul 2017 The Advantage for the First Mover in NASH is Limited, says Genfit After we reviewed NASH earlier this year, Genfit’s CSO, Dean Hum, came to speak at Refresh about his company’s strategy in the space. As CSO of Genfit, Dean Hum coordinates the company’s R&D efforts to be first to market in NASH, which represent an untapped market of €37B. The company is counting on its lead […] July 11, 2017 - 4 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
Interview 10 Jul 2017 Meet the CEO of Minoryx, the Spanish Biotech Fighting Rare Disease I spoke with Marc Martinell, CEO of Minoryx, to learn first-hand how his company in Barcelona is bringing new hope for patients suffering from rare diseases. Having previously worked in Crystax Pharmaceuticals and Oryzon Genomics, Marc Martinell is now CEO of one of Spain’s most successful biotechs. Minoryx Therapeutics is developing what could be the first […] July 10, 2017 - 6 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Interview 7 Jul 2017 Video: The Naked Truth – How to Choose the Best Clinical Development Vendor! Two experts share their views on how to choose the best clinical development vendor. The selection process involves many different and varied factors! “Nowadays, vendor selection is part of a science, the science of making difficult choices,” Marc Riteco, Vice President of Clinical Development at uniQure, told the audience during our second Refresh Expert Track […] July 7, 2017 - 2 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
Interview 6 Jul 2017 Watch Europe’s Rising Biotech Startups Battle it out at Refresh After the early stage startups gave it all on stage, it was the turn of the more advanced biotechs to fight each other at Labiotech Refresh 2017. The first contestant was Beroceutica, a startup from Germany that uses artificial intelligence to look for biomarkers that allow better patient stratification in clinical trials. The goal is to increase the success […] July 6, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Interview 3 Jul 2017 Video: Is mRNA a True Game-Changer? Fireside Chat with Sean Marett, COO of BioNTech Sean Marett took a red-eye from New York to speak at Refresh last month: here are his thoughts on how mRNA therapeutics are taking biotech by storm! mRNA has become one of the next big things in biotech, and Germany-based BioNTech is at the forefront of the wave, developing personalized treatments for cancer. “We try to provide individualized […] July 3, 2017 - 1 minutemin - By Evelyn Warner Share WhatsApp Twitter Linkedin Email